NK - NantKwest, Inc.
| Previous Close | 1.3700 |
| Open | 1.4100 |
| Bid | 1.34 x 1100 |
| Ask | 1.41 x 1300 |
| Day's Range | 1.3400 - 1.4100 |
| 52 Week Range | 0.9300 - 5.4700 |
| Volume | 138,116 |
| Avg. Volume | 600,829 |
| Market Cap | 106.955M |
| Beta (3Y Monthly) | 3.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.31 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.83 |
- Zacks•11 days ago
Is the Options Market Predicting a Spike in NantKwest (NK) Stock?
Investors need to pay close attention to NantKwest (NK) stock based on the movements in the options market lately.
- Business Wire•12 days ago
NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
NantKwest’s phase II immunotherapy trial builds upon the company’s earlier phase II single-combination study using its proprietary, off-the-shelf aNKTM natural killer cell therapy and IL-15/Fc superagonist (N-803), which produced an objective responses in 3 of 7 patients.
- American City Business Journals•13 days ago
Soon-Shiong’s NantCell gets $30 million from Celgene
NantCell, a cancer treatment company founded by biotech entrepreneur Dr. Patrick Soon-Shiong, has received an additional $30 million investment from drug maker Celgene Corp.
- Business Wire•16 days ago
NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
NantKwest (NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases today announced that the company will be hosting an Investor/Analyst Day on Tuesday, January 8, 2019 in San Francisco, California. At this event, senior management of NantKwest will provide a review of its ongoing R&D program, as well as provide a roadmap for the company’s clinical programs for 2019.
- Simply Wall St.•27 days ago
Have Insiders Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Insider Monkey•last month
Is Nantkwest Inc (NK) Going to Burn These Hedge Funds?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]
- Business Wire•2 months ago
NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
Novel Trisprcific CD19.t-haNKTM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma
- Motley Fool•2 months ago
Here's Why NantKwest Skyrocketed 26.4% Today
Early-stage results for a new approach to fighting cancer are sparking investors' optimism.
- ACCESSWIRE•2 months ago
Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc.
CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / The US healthcare market is seeing a higher levels of acquisition activity as providers race to capitalize on innovation and deliver a better consumer experience. Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest said, "High dose, uninformed, toxic chemotherapy damages the immune system and induces what is known as tolerogenic cell death.
- Business Wire•2 months ago
NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
CULVER CITY, Calif.-- -- Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination as Outpatients with No Immune-Related Adverse Events In Highly Refractory Late-Stage Advanced Metastatic Triple ...
- Business Wire•2 months ago
NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
Update on Off-The-Shelf CD16 Targeted NK Cell and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head
- Zacks•3 months ago
NantKwest Sees Hammer Chart Pattern: Time to Buy?
NantKwest has been struggling lately, but the selling pressure may be coming to an end soon.
- Business Wire•4 months ago
NantKwest to Present at 2018 Cantor Global Healthcare Conference
NantKwest , a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2nd in New York City During the conference, company management will be presenting a corporate overview, as well as conducting one-on-one meetings to provide a corporate update, as well as review ...
Simply Wall St.•4 months agoWho Are The Top Investors In NantKwest Inc (NASDAQ:NK)?
A look at the shareholders of NantKwest Inc (NASDAQ:NK) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owningRead More...
- Benzinga•5 months ago
Citigroup Upgrades NantKwest, But Finds Six Reasons To Stay On Sidelines
Nantkwest Inc (NASDAQ: NK )'s enterprise value has fallen to about $120 million, limiting any potential downside, according to Citigroup. The Analyst Analyst Wendy Nicholson downgraded NantKwest from ...
- Business Wire•7 months ago
NantKwest Names Sonja Nelson Chief Financial Officer
NantKwest, Inc. today announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer .
- Reuters•7 months ago
Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
Billionaire Patrick Soon-Shiong plans to take an experimental cancer treatment company public this year and has begun hiring bankers, the biotechnology entrepreneur told Reuters. The former surgeon said in a recent interview that the new company, to be called Nant, would use most of the money raised from the initial public offering to develop a pipeline of cancer drugs, although the amount of financing has yet to be determined. Soon-Shiong made billions by founding and selling an injectable drugmaker, followed by a company that developed a way to make a chemotherapy drug more effective.
- Business Wire•8 months ago
NantKwest to Present at Jefferies 2018 Global Healthcare Conference
NantKwest , a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest, will be presenting and conducting one-on-one meetings at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 6, 2018.
- Business Wire•9 months ago
NantKwest to Present at Upcoming Science & Medicine Conferences
NantKwest , a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at two science and medicine conferences in the months of April and May 2018.
- Business Wire•10 months ago
NantKwest to Present at Upcoming Investment and Healthcare Conferences
NantKwest , a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the month of March and April 2018.
- Business Wire•11 months ago
Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
NantKwest Inc. , a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer cells to treat cancer, today announced that the first patient has been dosed in a first-in-human, Phase I clinical study in glioblastoma of HER2.taNK, a novel, natural killer cell-based immuno-oncology therapy using CAR technology in patients. The ...
